Lyell Immunopharma (LYEL) Asset Utilization Ratio (2021 - 2026)

Lyell Immunopharma has reported Asset Utilization Ratio for 6 years, with the latest figure at 0.0 in Q1 2026.

• Quarterly Asset Utilization Ratio fell 36.43% year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (down 36.43% YoY) and the FY2025 annual result came in at 0.0, down 11.86% from the prior year.
• Asset Utilization Ratio eased to 0.0 in Q1 2026 per LYEL's latest filing, from 0.0 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 0.09 in Q1 2023 and troughed at 0.0 in Q2 2024.
• A 5-year average of 0.02 and a median of 0.0 in 2025 frame the typical range for Asset Utilization Ratio.
• The sharpest annual moves came in 2023 and 2024: Asset Utilization Ratio surged 1063.08% in 2023, then slumped 99.9% in 2024.
• Over 5 years, Asset Utilization Ratio stood at 0.09 in 2022, then sank by 99.81% to 0.0 in 2023, then sank by 34.69% to 0.0 in 2024, then declined by 12.42% to 0.0 in 2025, then slipped by 6.74% to 0.0 in 2026.
• According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.0, 0.0, and 0.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.